Literature DB >> 22350799

Adaptive optimal design for bridging studies with an application to population pharmacokinetic studies.

Lee Kien Foo1, Stephen Duffull.   

Abstract

PURPOSE: To develop and evaluate methods for conducting adaptive population pharmacokinetic bridging studies.
METHODS: An adaptive D-optimal design based on optimization of the population Fisher information matrix was used to determine the best sampling schedule for a target-population. Recruitment of the target-population was divided into batches and patients are assumed to enroll by batch. A prior-population model was used to determine the optimal sampling schedule for the first batch and to stabilise the data analysis in the interim iteration. Simulation studies were performed under two scenarios (1) the prior- and target-populations have similar pharmacokinetic profiles and (2) the pharmacokinetic profiles diverge significantly. A design criterion to determine early full enrollment was also proposed.
RESULTS: The target-population estimates obtained using the proposed method were compared to estimates obtained if the target-population was studied with a design optimized based on the prior-population model. The proposed method is shown to be not inferior in scenario (1) and superior in scenario (2). The criterion to determine early full enrollment was proven to be effective.
CONCLUSIONS: An adaptive optimal design method together with an early full enrollment criterion were evaluated and resulted in more accurate estimates for the target-population in bridging studies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22350799     DOI: 10.1007/s11095-011-0659-3

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  15 in total

1.  Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs.

Authors:  S Retout; S Duffull; F Mentré
Journal:  Comput Methods Programs Biomed       Date:  2001-05       Impact factor: 5.428

2.  Bridging studies in clinical development.

Authors:  Jen-pei Liu; Shein-Chung Chow
Journal:  J Biopharm Stat       Date:  2002-08       Impact factor: 1.051

3.  Methods of robust design of nonlinear models with an application to pharmacokinetics.

Authors:  Lee-Kien Foo; Stephen Duffull
Journal:  J Biopharm Stat       Date:  2010-07       Impact factor: 1.051

4.  Robust population pharmacokinetic experiment design.

Authors:  Michael G Dodds; Andrew C Hooker; Paolo Vicini
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-02       Impact factor: 2.745

5.  Adaptive designs for dose-finding studies based on sigmoid Emax model.

Authors:  Vladimir Dragalin; Francis Hsuan; S Krishna Padmanabhan
Journal:  J Biopharm Stat       Date:  2007       Impact factor: 1.051

6.  Optimal design for multivariate response pharmacokinetic models.

Authors:  Ivelina Gueorguieva; Leon Aarons; Kayode Ogungbenro; Karin M Jorga; Trudy Rodgers; Malcolm Rowland
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-03-21       Impact factor: 2.745

7.  Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies.

Authors:  Radojka M Savic; Daniël M Jonker; Thomas Kerbusch; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-07-26       Impact factor: 2.745

8.  Incorporating prior parameter uncertainty in the design of sampling schedules for pharmacokinetic parameter estimation experiments.

Authors:  D Z D'Argenio
Journal:  Math Biosci       Date:  1990-04       Impact factor: 2.144

9.  Optimal experiment design for nonlinear models subject to large prior uncertainties.

Authors:  E Walter; L Pronzato
Journal:  Am J Physiol       Date:  1987-09

10.  Implementation of an adaptive group sequential design in a bioequivalence study.

Authors:  Nibedita Bandyopadhyay; Vladimir Dragalin
Journal:  Pharm Stat       Date:  2007 Apr-Jun       Impact factor: 1.894

View more
  14 in total

1.  Prediction of shrinkage of individual parameters using the bayesian information matrix in non-linear mixed effect models with evaluation in pharmacokinetics.

Authors:  François Pierre Combes; Sylvie Retout; Nicolas Frey; France Mentré
Journal:  Pharm Res       Date:  2013-06-07       Impact factor: 4.200

2.  Influence of the Size of Cohorts in Adaptive Design for Nonlinear Mixed Effects Models: An Evaluation by Simulation for a Pharmacokinetic and Pharmacodynamic Model for a Biomarker in Oncology.

Authors:  Giulia Lestini; Cyrielle Dumont; France Mentré
Journal:  Pharm Res       Date:  2015-06-30       Impact factor: 4.200

3.  Application of Adaptive DP-optimality to Design a Pilot Study for a Clotting Time Test for Enoxaparin.

Authors:  Abhishek Gulati; James M Faed; Geoffrey K Isbister; Stephen B Duffull
Journal:  Pharm Res       Date:  2015-07-01       Impact factor: 4.200

4.  Optimal sampling times for a drug and its metabolite using SIMCYP(®) simulations as prior information.

Authors:  Cyrielle Dumont; France Mentré; Clare Gaynor; Karl Brendel; Charlotte Gesson; Marylore Chenel
Journal:  Clin Pharmacokinet       Date:  2013-01       Impact factor: 6.447

Review 5.  Optimizing drug development of anti-cancer drugs in children using modelling and simulation.

Authors:  Johan G C van Hasselt; Natasha K A van Eijkelenburg; Jos H Beijnen; Jan H M Schellens; Alwin D R Huitema
Journal:  Br J Clin Pharmacol       Date:  2013-07       Impact factor: 4.335

6.  Optimal sampling of antipsychotic medicines: a pharmacometric approach for clinical practice.

Authors:  Vidya Perera; Robert R Bies; Gary Mo; Michael J Dolton; Vaughan J Carr; Andrew J McLachlan; Richard O Day; Thomas M Polasek; Alan Forrest
Journal:  Br J Clin Pharmacol       Date:  2014-10       Impact factor: 4.335

7.  Assessing robustness of designs for random effects parameters for nonlinear mixed-effects models.

Authors:  Stephen B Duffull; Andrew C Hooker
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-10-24       Impact factor: 2.745

8.  Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in Oncology.

Authors:  Philippe B Pierrillas; Sylvain Fouliard; Marylore Chenel; Andrew C Hooker; Lena E Friberg; Mats O Karlsson
Journal:  AAPS J       Date:  2018-03-07       Impact factor: 4.009

9.  Current Use and Developments Needed for Optimal Design in Pharmacometrics: A Study Performed Among DDMoRe's European Federation of Pharmaceutical Industries and Associations Members.

Authors:  F Mentré; M Chenel; E Comets; J Grevel; A Hooker; M O Karlsson; M Lavielle; I Gueorguieva
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-06-05

10.  Use of Modeling and Simulation in the Design and Conduct of Pediatric Clinical Trials and the Optimization of Individualized Dosing Regimens.

Authors:  C Stockmann; J S Barrett; J K Roberts; Cmt Sherwin
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-11-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.